Farabaugh Amy, Sonawalla Shamsah, Johnson Daniel P, Witte Janet, Papakostas George I, Goodness Tracie, Clain Alisabet, Baer Lee, Mischoulon David, Fava Maurizio, Harley Rebecca
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA USA.
Ann Clin Psychiatry. 2010 Aug;22(3):166-71.
The purpose of this study was to examine whether treatment response to fluoxetine by depressed outpatients was predicted by early improvement on any of 3 subscales (Anxiety, Depression, and Anger/Hostility) of the Symptom Questionnaire (SQ).
We evaluated 169 depressed outpatients (52.6% female) between ages 18 and 65 (mean age, 40.3 +/- 10.6 years) meeting DSM-IIIR criteria for major depressive disorder (MDD). All patients completed the SQ at baseline (week 0) and at weeks 2, 4, and 8 of treatment with fluoxetine 20 mg/d. We defined treatment response as a > or= 50% reduction in score on the 17-item Hamilton Rating Scale for Depression, and early improvement on 3 SQ subscales (Anxiety, Depression, and Anger/Hostility) as a >30% reduction in score by week 2.
The percentage of patients with significant early improvement in anger was significantly greater than the percentage of those with early improvements in anxiety or depression. When early improvement on the Anxiety, Depression, and Anger/Hostility subscales of the SQ were assessed independently by logistic regression, all 3 subscales were predictors of response to treatment.
Early improvement in anger, anxiety, and depressive symptoms may predict response to antidepressant treatment among outpatients with MDD.
本研究旨在探讨症状问卷(SQ)的3个分量表(焦虑、抑郁和愤怒/敌意)中任何一个分量表的早期改善是否能预测抑郁症门诊患者对氟西汀的治疗反应。
我们评估了169名年龄在18至65岁之间(平均年龄40.3±10.6岁)符合DSM-IIIR重性抑郁症(MDD)标准的抑郁症门诊患者(女性占52.6%)。所有患者在基线(第0周)以及接受20mg/d氟西汀治疗的第2、4和8周时均完成了症状问卷。我们将治疗反应定义为17项汉密尔顿抑郁评定量表得分降低≥50%,并将症状问卷3个分量表(焦虑、抑郁和愤怒/敌意)的早期改善定义为到第2周时得分降低>30%。
愤怒方面有显著早期改善的患者百分比显著高于焦虑或抑郁方面有早期改善的患者百分比。当通过逻辑回归独立评估症状问卷的焦虑、抑郁和愤怒/敌意分量表的早期改善情况时,所有3个分量表都是治疗反应的预测指标。
愤怒、焦虑和抑郁症状的早期改善可能预示着重性抑郁症门诊患者对抗抑郁治疗的反应。